Continuous-flow left ventricular assist devices (LVADs) subject elements of the blood to significant stress, resulting in clinically significant and subclinical hemolysis. We sought to prospectively determine whether baseline red-cell osmotic fragility of an advanced heart-failure patient influences the hemolytic response to LVAD support. Osmotic fragility assesses the degree of red-blood-cell hemolysis under varying degrees of osmotic stress. Assays were prospectively obtained on 50 consecutive patients prior to placement of continuous-flow LVADs: HeartMate II (n = 34), Jarvik 2000 (n = 5), HeartWare (n = 6). The mean age of the patients was 60.2 years and 87% were male and 47% were nonischemic. The overall median post-LVAD lactate dehydrogenase (LDH) was 583 (427-965), and there was no difference between devices. Mean hemolysis was 15.68 ± 12.96% at 0.45% NaCl (the inflection point of the osmotic fragility hemolysis curve). A scatter plot did not reveal any relationship between preoperative osmotic fragility and postoperative LDH. Linear regression confirmed no predictive relationship (p = 0.71). In conclusion, preoperative variations in osmotic fragility do not appear to account for differences in hemolysis following ventricular assist device placement. Mechanical forces generated by existing LVADs result in similar levels of biochemical hemolysis, as assessed by LDH, despite baseline differences in a patient's osmotic red-cell fragility. ASAIO Journal 2014; 60:524-528.
Use of ventricular assist devices (VADs) has led to markedly improved survival rate and quality of life for patients with advanced heart failure, but these devices carry significant risks, including pump thrombosis, stroke, and life-threatening bleeding. 1, 2 The inherent need for anticoagulation in the face of an environment that is conducive to bleeding challenges all clinicians caring for these patients. Major bleeding events have ranged from 1.13 to 1.66 per patient-year for continuous-flow devices. Conversely, thromboembolic events can result in ischemic stroke, peripheral arterial thrombosis, or pump thrombosis. [1] [2] [3] Pump thrombosis is relatively uncommon (0.02-0.03 events per patient-year) but remains one of the most feared complications of VAD therapy, and its incidence appears to be rising. 1, 2, 4, 5 A recent analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) noted that pump thrombosis and pump-related hemolysis were identified in 54% of patients who underwent pump exchange. 6 In addition to those who actually develop pump thrombosis, all patients who received current-generation left VADs (LVADs) presented with some degree of increased lactate dehydrogenase (LDH). Indeed, the elevated levels of LDH and plasmafree hemoglobin, markers for hemolysis, are frequently seen at the time of VAD complications as well as during support with normally functioning devices. 7, 8 Interagency Registry for Mechanically Assisted Circulatory Support defines hemolysis as a plasma-free hemoglobin value of greater than 40 mg/dl in association with clinical signs of hemolysis. This level of plasma-free hemoglobin is much higher than the level defined as normal, that is, below 5 mg/ dl, in patients without mechanical circulatory support. This is reflective of the supra-physiologic levels of hemolysis generated by all current-generation VADs. 6, 9, 10 The implications of lesser, subclinical elevations in hemolysis remain clinically unknown, although higher degrees of hemolysis as measured by elevation in LDH have clearly been linked to device complications. 11 The recognition of this relationship prompted many centers to routinely screen for hemolysis following LVAD placement. 12, 13 To date, scant information exists defining which advanced heart failure patients may be more or less prone to develop post-LVAD hemolysis and the clinically significant effects of lesser degrees of hemolysis. As such, we sought to determine whether the baseline osmotic stability of a red blood cell (RBC) influenced the ability of the RBC to withstand the mechanical forces of continuous-flow VADs. The osmotic fragility assay has been traditionally used to evaluate patients with certain RBC membrane defects, such as hereditary spherocytosis. Erythrocyte osmotic fragility can be directly assayed and does correlate to the severity of disease and degree of clinically significant hemolysis seen in these patients. 14, 15 Although patients with certain RBC membrane defects represent one end of the osmotic fragility spectrum, patients without such membrane cell defects will have RBCs that are relatively more or less resistant to hemolysis under osmotic stress. with the potential for differential RBC osmotic fragility, we prospectively investigated the degree to which the patient's baseline red-cell fragility, as measured by osmotic fragility, contributes to the degree of post-VAD hemolysis.
Methods

Study Patients
osmotic fragility assays were prospectively obtained prior to LVAD placement on 50 consecutive patients from february 2011 to September 2012. five patients were excluded from analysis due to the presence of a mechanical circulatory support at the time of VAD placement (extracorporeal membrane oxygenation or percutaneous support). furthermore, no patients with biventricular devices were included. The remaining 45 patients were included in the analysis. The primary hypothesis was that preimplant red blood osmotic cell fragility would impact postimplant hemolysis (as measured by LDH) in patients undergoing LVAD placement.
Two patient groups were defined, one with high osmotic fragility and the other with low osmotic fragility, on the basis of whether the percent hemolysis was above or below the median. Baseline characteristics, including medications and hemodynamic parameters, were recorded as the most recent values available prior to LVAD placement. Length of stay was defined as starting with the date of LVAD implantation until discharge. The study was approved by the University of Utah institutional review board.
Laboratory Analysis
Erythrocyte osmotic fragility assay was performed using spectrophotometry to quantify the percent erythrocyte hemolysis under varying osmotic stresses ranging from 0.9% sodium chloride (NaCl) to 0% NaCl (water). Percent hemolysis in 0.45% NaCl (the approximate inflection point of the osmotic fragility inflection curve) was used to define two groups (low fragility and high fragility) with osmotic fragility below and above the median, respectively. Lactate dehydrogenase was measured as total serum LDH using a quantitative enzymatic assay, normal range 100-253 U/L. This LDH level was obtained as close to 4 weeks postoperatively as possible or at discharge to attempt to diminish the effect of perioperative LDH elevations. Lactate dehydrogenase results are reported as median and interquartile range (IQR). All laboratory analyses were performed at the University of Utah ARUP National Reference Laboratory (Salt Lake City, UT). 
Statistical Analysis
Descriptive statistics were expressed as mean ± standard deviation, median with IQR or percentages. Length of stay, follow-up time, and survival were described using median with IQR. Categorical variables were analyzed using the χ 2 test or fisher's exact test when expected cell counts were less than 5. Student's t-test (two-tailed) was used to compare continuous variables. Linear regression was used to test the relationship between pre-VAD osmotic fragility and post-VAD LDH. Survival analysis was performed using the kaplan-Meier method with log-rank test to compare survival curves. A p value less than 0.05 was considered significant. All analyses were performed using Stata 12.1 (StataCorp. 2011, College Station, TX).
Results
forty-five patients with a mean age of 60.2 ± 13.5 years underwent LVAD placement for New york Heart Association class IV heart failure. of these, 86.6% were male and 53% had heart failure due to ischemic cardiomyopathy. Baseline patient characteristics, including hemodynamic parameters and concomitant medications, are listed in Table 1 . The high-osmoticfragility patients had significantly more hemolysis in 0.45% NaCl than the low-osmotic-fragility patients (p < 0.001), indicating we had good separation between groups based on our definition. The high-osmotic-fragility patients were older (64.4 vs. 55.9) by an average of 8.5 years (p = 0.03). The highosmotic-fragility patients were also more likely to be on a beta-blocker at the time of admission prior to VAD placement (35% vs. 5%, p = 0.01). otherwise these two groups were similar in their baseline characteristics.
Three continuous-flow VAD device types were utilized: Heartmate II, Heartware, and Jarvik 2000. The majority of patients (75.6%) received the Heartmate II device, and 13.3% received the Heartware device and 11.1% received a Jarvik 2000. The different devices were used at similar rates among both patient groups ( Table 2) .
There was no difference in postoperative LDH levels between the high-osmotic-fragility and low-osmotic-fragility patients (median 562 [IQR: 506-936] vs. 704 [427-1,014], p = 0.81). Individual percent hemolysis in 0.45% NaCl versus postoperative LDH was graphed using a scatter plot (Figure 1) . The scatter plot revealed neither a clear relationship nor a need for data transformation. Linear regression confirmed no predictive relationship between preoperative osmotic fragility and postoperative LDH (p = 0.71).
Median follow-up duration was 9.1 months (IQR: 3.4-14.4 months) overall and was similar in both groups. Length of stay and postoperative complications were similar between groups ( Table 3) . As depicted in Figure 2 , there was no difference in the rate of survival between the high-and low-osmotic-fragility groups (p = 0.64).
Discussion
we hypothesized that baseline red-cell osmotic fragility would impact postimplant hemolysis rates in patients receiving continuous-flow LVADs. Alternatively, we observed, in this relatively small group of patients, that preoperative osmotic fragility has no predictable influence on post-LVAD hemolysis. The majority of patients with durable LVADs have supraphysiologic, and quite possibly clinically irrelevant, levels of hemolysis as witnessed by elevations in clinical markers of hemolysis. Even more marked elevations in LDH and/or plasma-free hemoglobin are often identified at the time of thrombotic complications, including pump thrombosis. This increase in hemolysis is typically thought to be a consequence and a marker of the thrombotic event.
whereas increased hemolysis in patients undergoing VAD therapy often prompts an investigation for complications such as device thrombosis, hemolysis itself can actually drive thrombosis secondary to adenosine diphosphate release, which is a potent platelet activator. In addition, plasma-free hemoglobin is liberated, which lowers the bioavailability of nitric oxide, in turn enhancing platelet activation. 16 In this way, the supra-physiologic levels of hemolysis generated by currentgeneration ventricular assist devices may actually contribute to thrombosis of the device itself through platelet activation. Currently, it is not known whether these or other mechanisms are responsible for the reported recent increase in LVAD thrombosis, but this increase has been associated with a significant increase in morbidity and mortality. 5, 17 whereas much interest is focused on a particular pump's proclivity to pump-induced hemolysis, we observed no differences between second-and third-generation pumps (admittedly the relative numbers are too small to draw firm conclusions). Theoretically, the axial flow pumps might provide a more "harsh" environment; that is, if there is a proclivity to RBC fragility, it might lead to more hemolysis. 18, 19 To date, few preoperative risk factors have been identified that predict increased levels of postoperative hemolysis. Recently, glucose 6-phosphatase deficiency (G6PD), though present in only a small segment of patients, has been associated with increased hemolytic events following VAD placement. 20 The underlying ethnic mix of this cohort is primarily Caucasian, which may be a limitation as some conditions that predispose individuals to hemolysis, such as G6PD, are more prevalent in non-Caucasian populations. In our cohort, patients with high osmotic fragility were older, but this ultimately did result in differences in post-VAD hemolysis.
This study has several limitations. Lactate dehydrogenase is not a perfect marker for RBC hemolysis. whereas LDH is commonly used to screen for RBC hemolysis, INTERMACS and other organizations use elevations in plasma-free hemoglobin to define hemolysis. At the time of this study, plasmafree hemoglobin was used in our center as a confirmatory test when clinical concern of marked hemolysis was high, while LDH was obtained routinely. 21, 22 In addition, factors such as recent transfusion and serum osmolality may affect the osmotic fragility assay result, and our patients' transfusion status and osmolality at the time of their osmotic fragility assay is unknown. 23 finally, osmotic fragility measures one specific aspect of RBC fragility, that being the hemolytic response of the RBC when placed under various degrees of osmotic stress. whereas the effects of osmotic fragility on hemolysis in LVAD patients has not been previously published, in other model systems osmotic fragility does not necessarily predict RBC deformability or the hemolytic response to mechanical stress. 24, 25 Although we saw no predictive relationship between preimplant osmotic fragility and post-VAD hemolysis, other measurements of RBC fragility to mechanical/sheer stresses may be more likely to predict post-VAD hemolysis.
Conclusions
The ability to preoperatively identify which patients are at higher risk for postoperative hemolysis and thromboembolic complications would significantly aid in patient selection and counseling as well as provide valuable clinical information to guide individualized postimplantation antiplatelet and anticoagulation strategies. The present study demonstrates that preoperative variations in osmotic fragility do not appear to account for differences in hemolysis following LVAD placement. Mechanical forces generated by existing LVADs result in similar levels of biochemical hemolysis, as assessed by LDH, despite baseline differences in a patient's red-cell osmotic fragility.
